{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T04:57:36Z","timestamp":1781413056553,"version":"3.54.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001793","name":"Queensland University of Technology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001793","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Immunotherapy has transformed cancer treatment and outcomes. Patients receiving immunotherapy often encounter immune-related and treatment-related adverse events, leading to substantial supportive care needs. Currently, no recommendations exist to guide the use of non-pharmacological supportive care interventions for people with cancer undergoing immunotherapy treatments. This review aims to summarise the available evidence regarding non-pharmacological supportive care strategies to inform future clinical management and research directions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Six electronic databases (PubMed, CINAHL, EMBASE, PsycInfo, Web of Science and Scopus) were systematically searched for studies on non-pharmacological supportive care interventions for adults undergoing immunotherapy, published from October 2014 to October 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 5383 studies were screened, with 14 meeting the inclusion criteria. Five were interventional studies and ten were observational. The interventional studies included three physical activity and exercise interventions, two dietary interventions, and one multimodal intervention. Most interventions were found to be feasible, acceptable, and demonstrate preliminary efficacy at improving quality of life, symptom burden, and clinical outcomes. Observational evidence demonstrated associations between physical activity and dietary factors and improved quality of life, reduced symptom burden, and improved clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Growing observational and preliminary interventional evidence suggests a multimodal supportive care intervention that includes regular symptom monitoring, dietary support and exercise to address the physical and psychosocial needs of cancer patients undergoing immunotherapy may be beneficial. However, further high-quality trials are needed to confirm their efficacy and inform clinical implementation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11912-025-01714-x","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T02:26:49Z","timestamp":1764988009000},"page":"1507-1523","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Non-pharmacological Supportive Care Interventions during Immunotherapy for People with Cancer: A Systematic Scoping Review and Future Directions"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0434-720X","authenticated-orcid":false,"given":"Morgan J.","family":"Farley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brighid","family":"Scanlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Crichton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Bigaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas H.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patsy M.","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Eastgate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"issue":"12","key":"1714_CR1","first-page":"6111","volume":"28","author":"AG Blidner","year":"2020","unstructured":"Blidner AG, et al. Cancer immunotherapy-related adverse events: causes and challenges. Support Care Cancer. 2020;28(12):6111\u20137.","journal-title":"Support Care Cancer"},{"issue":"2","key":"1714_CR2","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3390\/pharmaceutics15020504","volume":"5","author":"P Muthukutty","year":"2023","unstructured":"Muthukutty P, et al. Recent Adv Cancer Immunotherapy Delivery Modalities Pharm. 2023;5(2):504. https:\/\/doi.org\/10.3390\/pharmaceutics15020504.","journal-title":"Recent Adv Cancer Immunotherapy Delivery Modalities Pharm"},{"issue":"5256","key":"1714_CR3","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734\u20136.","journal-title":"Science"},{"key":"1714_CR4","doi-asserted-by":"crossref","unstructured":"Prasad VH, Oliver AT. Updated estimates of eligibility and response: Immune checkpoint inhibitors. J Clin Oncol. 2024;42(16).","DOI":"10.1200\/JCO.2024.42.16_suppl.e14613"},{"key":"1714_CR5","doi-asserted-by":"publisher","unstructured":"Barron CC, et al. Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review. J Immunother Cancer. 2023;11(8). https:\/\/doi.org\/10.1136\/jitc-2022-006500.","DOI":"10.1136\/jitc-2022-006500"},{"key":"1714_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348.","journal-title":"Eur J Cancer"},{"key":"1714_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1508512","volume":"16","author":"Q Fang","year":"2025","unstructured":"Fang Q, et al. Predictors of severity and onset timing of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a retrospective analysis. Front Immunol. 2025;16:1508512.","journal-title":"Front Immunol"},{"issue":"OCE4","key":"1714_CR8","doi-asserted-by":"publisher","first-page":"pE211","DOI":"10.1017\/S0029665115002530","volume":"74","author":"L Daly","year":"2015","unstructured":"Daly L, et al. Longitudinal changes in body composition during ipilimumab treatment for metastatic melanoma. Proc Nutr Soc. 2015;74(OCE4):pE211.","journal-title":"Proc Nutr Soc"},{"key":"1714_CR9","doi-asserted-by":"publisher","DOI":"10.1200\/OP.24.00037","author":"J Lai-Kwon","year":"2024","unstructured":"Lai-Kwon J, et al. Selecting immune checkpoint inhibitor side effects for real-time monitoring in routine cancer care: a modified Delphi study. JCO Oncol Pract. 2024. https:\/\/doi.org\/10.1200\/OP.24.00037.","journal-title":"JCO Oncol Pract"},{"issue":"36","key":"1714_CR10","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073\u2013126.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1714_CR11","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1158\/1078-0432.CCR-22-3181","volume":"29","author":"RS Goodman","year":"2023","unstructured":"Goodman RS, Johnson DB, Balko JM. Corticosteroids Cancer Immunotherapy. Clin Cancer Res. 2023;29(14):2580\u20137.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"1714_CR12","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.3390\/cancers15153860","volume":"15","author":"F Scotte","year":"2023","unstructured":"Scotte F, Taylor A, Davies A. Supportive Care: Keyst Mod Oncol Pract Cancers (Basel). 2023;15(15):3860. https:\/\/doi.org\/10.3390\/cancers15153860.","journal-title":"Supportive Care: Keyst Mod Oncol Pract Cancers (Basel)"},{"issue":"4","key":"1714_CR13","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/jnci\/djab223","volume":"114","author":"MA Mollica","year":"2022","unstructured":"Mollica MA, et al. Survivorship for individuals living with advanced and metastatic cancers: national cancer Institute meeting report. J Natl Cancer Inst. 2022;114(4):489\u201395.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"1714_CR14","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1093\/annonc\/mdx205","volume":"28","author":"HM Dhillon","year":"2017","unstructured":"Dhillon HM, et al. Impact of physical activity on fatigue and quality of life in people with advanced lung cancer: a randomized controlled trial. Ann Oncol. 2017;28(8):1889\u201397.","journal-title":"Ann Oncol"},{"issue":"34","key":"1714_CR15","doi-asserted-by":"publisher","first-page":"5285","DOI":"10.1200\/JCO.23.00871","volume":"41","author":"T Sanft","year":"2023","unstructured":"Sanft T, et al. Randomized trial of exercise and nutrition on chemotherapy completion and pathologic complete response in women with breast cancer: the lifestyle, exercise, and nutrition early after diagnosis study. J Clin Oncol. 2023;41(34):5285\u201395.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1714_CR16","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1093\/annonc\/mdx350","volume":"28","author":"A Molassiotis","year":"2017","unstructured":"Molassiotis A, et al. Mapping unmet supportive care needs, quality-of-life perceptions and current symptoms in cancer survivors across the Asia-Pacific region: results from the international STEP study. Ann Oncol. 2017;28(10):2552\u20138.","journal-title":"Ann Oncol"},{"issue":"1","key":"1714_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19\u201332.","journal-title":"Int J Soc Res Methodol"},{"key":"1714_CR18","unstructured":"Checklist for Systematic Reviews and Research Synthesis. 2020; Available from: https:\/\/jbi.global\/sites\/default\/files\/2020-08\/Checklist_for_Systematic_Reviews_and_Research_Syntheses.pdf"},{"key":"1714_CR19","unstructured":"PRISMA Statement. 2024; Available from: http:\/\/www.prisma-statement.org\/PRISMAStatement\/"},{"issue":"9","key":"1714_CR20","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/OP.23.00716","volume":"20","author":"NH Hart","year":"2024","unstructured":"Hart NH, et al. Survivorship care for people affected by advanced or metastatic cancer: MASCC-ASCO standards and practice recommendations. JCO Oncol Pract. 2024;20(9):1160\u201372.","journal-title":"JCO Oncol Pract"},{"key":"1714_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1538969","volume":"16","author":"S Zhao","year":"2025","unstructured":"Zhao S, et al. Assessing the impact of probiotics on immunotherapy effectiveness and antibiotic-mediated resistance in cancer: a systematic review and meta-analysis. Front Immunol. 2025;16:1538969.","journal-title":"Front Immunol"},{"key":"1714_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.mex.2023.102532","volume":"12","author":"S Mancin","year":"2024","unstructured":"Mancin S, et al. Systematic review of clinical practice guidelines and systematic reviews: a method for conducting comprehensive analysis. MethodsX. 2024;12:102532.","journal-title":"MethodsX"},{"key":"1714_CR23","unstructured":"Endnote. 2023; Available from: https:\/\/endnote.com\/downloads"},{"key":"1714_CR24","unstructured":"The World\u2019s #1 Systematic Review Tool. 2024; Available from: https:\/\/www.covidence.org\/"},{"issue":"9","key":"1714_CR25","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1177\/1357633X211021743","volume":"29","author":"C Charles","year":"2023","unstructured":"Charles C, et al. Delivering adapted physical activity by videoconference to patients with fatigue under immune checkpoint inhibitors: lessons learned from the PACTIMe-FEAS feasibility study. J Telemed Telecare. 2023;29(9):716\u201324.","journal-title":"J Telemed Telecare"},{"issue":"6","key":"1714_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjorl.2024.101493","volume":"90","author":"M Caballero-Borrego","year":"2024","unstructured":"Caballero-Borrego M, et al. Walking one hour per day and the derived neutrophil-to-lymphocyte ratio are associated with outcome in palliative second-line immunotherapy for patients with recurrent and\/or metastatic squamous cell carcinoma of head and neck. Braz J Otorhinolaryngol. 2024;90(6):101493.","journal-title":"Braz J Otorhinolaryngol"},{"issue":"13","key":"1714_CR27","doi-asserted-by":"publisher","first-page":"14694","DOI":"10.1002\/cam4.6091","volume":"12","author":"BJ Crosby","year":"2023","unstructured":"Crosby BJ, et al. Feasibility of supervised telehealth exercise for patients with advanced melanoma receiving checkpoint inhibitor therapy. Cancer Med. 2023;12(13):14694\u2013706.","journal-title":"Cancer Med"},{"issue":"4","key":"1714_CR28","first-page":"1497","volume":"27","author":"J Lacey","year":"2019","unstructured":"Lacey J, et al. A supportive care intervention for people with metastatic melanoma being treated with immunotherapy: a pilot study assessing feasibility, perceived benefit, and acceptability. Support Care Cancer. 2019;27(4):1497\u2013507.","journal-title":"Support Care Cancer"},{"issue":"13","key":"1714_CR29","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1002\/cncr.34718","volume":"129","author":"L Galus","year":"2023","unstructured":"Galus L, et al. Vitamin D supplementation increases objective response rate and prolongs progression-free time in patients with advanced melanoma undergoing anti-PD-1 therapy. Cancer. 2023;129(13):2047\u201355.","journal-title":"Cancer"},{"issue":"1","key":"1714_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01170-2","volume":"15","author":"Q Min","year":"2024","unstructured":"Min Q, Xianru S, Gengyun S. Effect of physical activity on patients of NSCLC. Discover Oncol. 2024;15(1):328.","journal-title":"Discover Oncol"},{"issue":"4","key":"1714_CR31","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1093\/jnci\/djad245","volume":"116","author":"RJ Verheijden","year":"2024","unstructured":"Verheijden RJ, et al. Physical activity and checkpoint inhibition: association with toxicity and survival. J Natl Cancer Inst. 2024;116(4):573\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1714_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00275-0","volume":"11","author":"XF Liu","year":"2022","unstructured":"Liu XF, et al. Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model. Exp Hematol Oncol. 2022;11(1):20.","journal-title":"Exp Hematol Oncol"},{"key":"1714_CR33","doi-asserted-by":"publisher","DOI":"10.1177\/1534735419864431","volume":"18","author":"A Hyatt","year":"2019","unstructured":"Hyatt A, et al. Exercise behaviors and fatigue in patients receiving immunotherapy for advanced melanoma: a cross-sectional survey via social media. Integr Cancer Ther. 2019;18:1534735419864431.","journal-title":"Integr Cancer Ther"},{"issue":"5","key":"1714_CR34","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1001\/jamaoncol.2022.7753","volume":"9","author":"LA Bolte","year":"2023","unstructured":"Bolte LA, et al. Association of a mediterranean diet with outcomes for patients treated with immune checkpoint blockade for advanced melanoma. JAMA Oncol. 2023;9(5):705\u20139.","journal-title":"JAMA Oncol"},{"issue":"11","key":"1714_CR35","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.1007\/s00262-023-03522-3","volume":"72","author":"M Bersanelli","year":"2023","unstructured":"Bersanelli M, et al. Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study. Cancer Immunol Immunother. 2023;72(11):3707\u201316.","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"1714_CR36","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.3390\/cancers15113052","volume":"15","author":"M Golcic","year":"2023","unstructured":"Golcic M, et al. Analysis of the gut Microbiome and dietary habits in metastatic melanoma patients with a complete and sustained response to immunotherapy. Cancers (Basel). 2023;15(11):3052. https:\/\/doi.org\/10.3390\/cancers15113052.","journal-title":"Cancers (Basel)."},{"issue":"11","key":"1714_CR37","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1038\/s41591-022-01965-2","volume":"28","author":"RC Simpson","year":"2022","unstructured":"Simpson RC, et al. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. Nat Med. 2022;28(11):2344\u201352.","journal-title":"Nat Med"},{"issue":"6575","key":"1714_CR38","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1126\/science.aaz7015","volume":"374","author":"CN Spencer","year":"2021","unstructured":"Spencer CN, et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021;374(6575):1632\u201340.","journal-title":"Science"},{"key":"1714_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103728","volume":"176","author":"NH Hart","year":"2022","unstructured":"Hart NH, et al. Unmet supportive care needs of people with advanced cancer and their caregivers: a systematic scoping review. Crit Rev Oncol Hematol. 2022;176:103728.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"1714_CR40","first-page":"6369","volume":"30","author":"HR Wardill","year":"2022","unstructured":"Wardill HR, et al. Dual contribution of the gut microbiome to immunotherapy efficacy and toxicity: supportive care implications and recommendations. Support Care Cancer. 2022;30(8):6369\u201373.","journal-title":"Support Care Cancer"},{"issue":"1","key":"1714_CR41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","volume":"18","author":"X Zhou","year":"2020","unstructured":"Zhou X, et al. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 2020;18(1):87.","journal-title":"BMC Med"},{"issue":"11","key":"1714_CR42","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1249\/MSS.0000000000002116","volume":"51","author":"KL Campbell","year":"2019","unstructured":"Campbell KL, et al. Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med Sci Sports Exerc. 2019;51(11):2375\u201390.","journal-title":"Med Sci Sports Exerc"},{"key":"1714_CR43","doi-asserted-by":"publisher","unstructured":"Courneya KS et al. Structured exercise after adjuvant chemotherapy for colon cancer. N Engl J Med. 2025;393(1):13\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2502760","DOI":"10.1056\/NEJMoa2502760"},{"key":"1714_CR44","doi-asserted-by":"publisher","unstructured":"Gustafson MP, et al. Exercise and the immune system: taking steps to improve responses to cancer immunotherapy. J Immunother Cancer. 2019;e001872.\u00a0https:\/\/doi.org\/10.1136\/jitc-2020-001872.","DOI":"10.1136\/jitc-2020-001872"},{"issue":"2","key":"1714_CR45","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1158\/2159-8290.CD-19-0790","volume":"10","author":"AJ Anandappa","year":"2020","unstructured":"Anandappa AJ, Wu CJ, Ott PA. Directing traffic: how to effectively drive T cells into tumors. Cancer Discov. 2020;10(2):185\u201397.","journal-title":"Cancer Discov"},{"issue":"7","key":"1714_CR46","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.ccell.2022.05.006","volume":"40","author":"E Kurz","year":"2022","unstructured":"Kurz E, et al. Exercise-induced engagement of the IL-15\/IL-15Ralpha axis promotes anti-tumor immunity in pancreatic cancer. Cancer Cell. 2022;40(7):720\u2013e7375.","journal-title":"Cancer Cell"},{"issue":"4","key":"1714_CR47","doi-asserted-by":"publisher","first-page":"452","DOI":"10.18632\/oncotarget.27464","volume":"11","author":"E Wennerberg","year":"2020","unstructured":"Wennerberg E, et al. Exercise reduces immune suppression and breast cancer progression in a preclinical model. Oncotarget. 2020;11(4):452\u201361.","journal-title":"Oncotarget."},{"key":"1714_CR48","first-page":"100","volume":"26","author":"A Martin-Ruiz","year":"2020","unstructured":"Martin-Ruiz A, et al. Benefits of exercise and immunotherapy in a murine model of human non-small-cell lung carcinoma. Exerc Immunol Rev. 2020;26:100\u201315.","journal-title":"Exerc Immunol Rev"},{"issue":"4","key":"1714_CR49","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/s41391-022-00624-4","volume":"26","author":"JS Kim","year":"2023","unstructured":"Kim JS, et al. Acute effect of high-intensity interval aerobic exercise on serum myokine levels and resulting tumour-suppressive effect in trained patients with advanced prostate cancer. Prostate Cancer Prostatic Dis. 2023;26(4):795\u2013801.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"1714_CR50","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.cmet.2016.01.011","volume":"23","author":"L Pedersen","year":"2016","unstructured":"Pedersen L, et al. Voluntary running suppresses tumor growth through epinephrine- and IL-6 dependent NK cell mobilization and redistribution. Cell Metab. 2016;23(3):554\u201362.","journal-title":"Cell Metab"},{"issue":"20","key":"1714_CR51","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1113\/JP286043","volume":"602","author":"MJ Farley","year":"2024","unstructured":"Farley MJ, et al. Interleukin-15 and high-intensity exercise: relationship with inflammation, body composition and fitness in cancer survivors. J Physiol. 2024;602(20):5203\u201315.","journal-title":"J Physiol"},{"issue":"6","key":"1714_CR52","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/bjsports-2015-094927","volume":"50","author":"T Li","year":"2016","unstructured":"Li T, et al. The dose-response effect of physical activity on cancer mortality: findings from 71 prospective cohort studies. Br J Sports Med. 2016;50(6):339\u201345.","journal-title":"Br J Sports Med"},{"issue":"4","key":"1714_CR53","doi-asserted-by":"publisher","first-page":"184","DOI":"10.5694\/mja18.00199","volume":"209","author":"P Cormie","year":"2018","unstructured":"Cormie P, et al. Clinical oncology society of Australia position statement on exercise in cancer care. Med J Aust. 2018;209(4):184\u20137.","journal-title":"Med J Aust"},{"key":"1714_CR54","doi-asserted-by":"crossref","unstructured":"Charles C et al. Delivering adapted physical activity by videoconference to patients with fatigue under immune checkpoint inhibitors: Lessons learned from the PACTIMe-FEAS feasibility study. J Telemed Telecare, 2021: 1357633x211021743.","DOI":"10.1177\/1357633X211021743"},{"issue":"3","key":"1714_CR55","first-page":"685","volume":"26","author":"BK Clifford","year":"2018","unstructured":"Clifford BK, et al. Barriers and facilitators of exercise experienced by cancer survivors: a mixed methods systematic review. Support Care Cancer. 2018;26(3):685\u2013700.","journal-title":"Support Care Cancer"},{"issue":"4","key":"1714_CR56","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/1747-0080.12631","volume":"77","author":"N Kiss","year":"2020","unstructured":"Kiss N, et al. Clinical oncology society of Australia: position statement on cancer-related malnutrition and sarcopenia. Nutr Diet. 2020;77(4):416\u201325.","journal-title":"Nutr Diet"},{"issue":"1","key":"1714_CR57","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/curroncol32010003","volume":"32","author":"S James","year":"2024","unstructured":"James S, et al. Nutritional counseling during chemotherapy treatment: a systematic review of feasibility, safety, and efficacy. Curr Oncol. 2024;32(1):3. https:\/\/doi.org\/10.3390\/curroncol32010003.","journal-title":"Curr Oncol."},{"issue":"23","key":"1714_CR58","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1002\/cncr.35043","volume":"129","author":"C Kudiarasu","year":"2023","unstructured":"Kudiarasu C, et al. What are the most effective exercise, physical activity and dietary interventions to improve body composition in women diagnosed with or at high-risk of breast cancer? A systematic review and network meta-analysis. Cancer. 2023;129(23):3697\u2013712.","journal-title":"Cancer"},{"issue":"2","key":"1714_CR59","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/jcsm.12928","volume":"13","author":"L Hanna","year":"2022","unstructured":"Hanna L, et al. Association between skeletal muscle mass and quality of life in adults with cancer: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2022;13(2):839\u201357.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"4","key":"1714_CR60","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1002\/jcsm.13256","volume":"14","author":"N Kiss","year":"2023","unstructured":"Kiss N, et al. Low muscle mass, malnutrition, sarcopenia, and associations with survival in adults with cancer in the UK biobank cohort. J Cachexia Sarcopenia Muscle. 2023;14(4):1775\u201388.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1714_CR61","doi-asserted-by":"crossref","unstructured":"Hu Q et al. Clinical Impact of Skeletal Muscle Mass and Nutritional Status in Patients with Recurrent or Advanced Gastric Cancer Treated with Nivolumab. Oncology, 2024: pp. 1\u20139.","DOI":"10.1159\/000540840"},{"key":"1714_CR62","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.clnu.2024.11.022","volume":"44","author":"B Gardiner","year":"2025","unstructured":"Gardiner B, et al. The impact of fibre and prebiotic interventions on outcomes in cancer and haematopoietic stem cell transplantation: a systematic review. Clin Nutr. 2025;44:86\u2013100.","journal-title":"Clin Nutr"},{"issue":"10","key":"1714_CR63","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.3390\/microorganisms10102048","volume":"10","author":"GH Al-Qadami","year":"2022","unstructured":"Al-Qadami GH, et al. Gut microbiota-derived short-chain fatty acids: impact on cancer treatment response and toxicities. Microorganisms. 2022;10(10):2048. https:\/\/doi.org\/10.3390\/microorganisms10102048.","journal-title":"Microorganisms."},{"issue":"8","key":"1714_CR64","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/s41591-021-01406-6","volume":"27","author":"MC Andrews","year":"2021","unstructured":"Andrews MC, et al. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021;27(8):1432\u201341.","journal-title":"Nat Med"},{"issue":"12","key":"1714_CR65","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1665973","volume":"8","author":"XZ Huang","year":"2019","unstructured":"Huang XZ, et al. Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients. Oncoimmunology. 2019;8(12):e1665973.","journal-title":"Oncoimmunology"},{"key":"1714_CR66","doi-asserted-by":"publisher","first-page":"1158200","DOI":"10.3389\/fimmu.2023.1158200","volume":"14","author":"Y Dong","year":"2023","unstructured":"Dong Y, et al. Gut microbiota-derived short-chain fatty acids regulate gastrointestinal tumor immunity: a novel therapeutic strategy? Front Immunol. 2023;14:1158200.","journal-title":"Front Immunol"},{"issue":"12","key":"1714_CR67","volume":"31","author":"NH Hart","year":"2023","unstructured":"Hart NH, et al. Exercise and the gut microbiome: implications for supportive care in cancer. Support Care Cancer. 2023;31(12):724.","journal-title":"Support Care Cancer"},{"issue":"1","key":"1714_CR68","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.clnu.2020.05.016","volume":"40","author":"BJ Baguley","year":"2021","unstructured":"Baguley BJ, et al. Mediterranean-style dietary pattern improves cancer-related fatigue and quality of life in men with prostate cancer treated with androgen deprivation therapy: a pilot randomised control trial. Clin Nutr. 2021;40(1):245\u201354.","journal-title":"Clin Nutr"},{"issue":"2","key":"1714_CR69","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jand.2020.08.077","volume":"121","author":"E Croisier","year":"2021","unstructured":"Croisier E, Brown T, Bauer J. The efficacy of dietary fiber in managing Gastrointestinal toxicity symptoms in patients with gynecologic cancers undergoing pelvic radiotherapy: A systematic review. J Acad Nutr Diet. 2021;121(2):261\u201377. e2.","journal-title":"J Acad Nutr Diet"},{"issue":"12","key":"1714_CR70","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.3390\/nu14122403","volume":"14","author":"M Crichton","year":"2022","unstructured":"Crichton M, et al. Non-pharmacological self-management strategies for Chemotherapy-induced peripheral neuropathy in people with advanced cancer: a systematic review and meta-analysis. Nutrients. 2022;14(12):2403. https:\/\/doi.org\/10.3390\/nu14122403.","journal-title":"Nutrients."},{"issue":"6","key":"1714_CR71","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1158\/1055-9965.EPI-19-1522","volume":"29","author":"JL Koole","year":"2020","unstructured":"Koole JL, et al. Higher serum vitamin D concentrations are longitudinally associated with better global quality of life and less fatigue in colorectal cancer survivors up to 2 years after treatment. Cancer Epidemiol Biomarkers Prev. 2020;29(6):1135\u201344.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1714_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101798","volume":"38","author":"E Han","year":"2023","unstructured":"Han E, et al. The relationship between dietary inflammatory potential and cancer outcomes among cancer survivors: a systematic review and meta-analysis of cohort studies. Transl Oncol. 2023;38:101798.","journal-title":"Transl Oncol"},{"issue":"5","key":"1714_CR73","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1016\/j.clnu.2021.02.005","volume":"40","author":"M Muscaritoli","year":"2021","unstructured":"Muscaritoli M, et al. Espen practical guideline: clinical nutrition in cancer. Clin Nutr. 2021;40(5):2898\u2013913.","journal-title":"Clin Nutr"},{"issue":"1","key":"1714_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-13234-1","volume":"24","author":"RM Farias","year":"2024","unstructured":"Farias RM, et al. Diet and immune effects trial (DIET)- a randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy. BMC Cancer. 2024;24(1):1493.","journal-title":"BMC Cancer"},{"issue":"3","key":"1714_CR75","doi-asserted-by":"publisher","first-page":"e224427","DOI":"10.1001\/jamanetworkopen.2022.4427","volume":"5","author":"L Zhang","year":"2022","unstructured":"Zhang L, et al. Efficiency of electronic health record assessment of Patient-Reported outcomes after cancer immunotherapy: a randomized clinical trial. JAMA Netw Open. 2022;5(3):e224427.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1714_CR76","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s11764-019-00770-0","volume":"13","author":"J Lai-Kwon","year":"2019","unstructured":"Lai-Kwon J, et al. The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors. J Cancer Surviv. 2019;13(4):503\u201311.","journal-title":"J Cancer Surviv"},{"issue":"2","key":"1714_CR77","first-page":"805","volume":"12","author":"Z Bi","year":"2022","unstructured":"Bi Z, et al. Negative correlations of psychological distress with quality of life and immunotherapy efficacy in patients with advanced NSCLC. Am J Cancer Res. 2022;12(2):805\u201315.","journal-title":"Am J Cancer Res"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01714-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-025-01714-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01714-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T09:02:22Z","timestamp":1766826142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-025-01714-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":77,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1714"],"URL":"https:\/\/doi.org\/10.1007\/s11912-025-01714-x","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors and our university consented to publishing our study in your journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors and our university consented to publish our study in your journal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}